帕唑帕尼对比安慰剂在转移性肾细胞癌转移灶切除术后无疾病证据患者中的随机双盲III期研究:ECOG-ACRIN E2810
这项随机双盲安慰剂对照多中心III期研究纳入129例转移灶切除术后无疾病证据的转移性肾细胞癌患者,1:1随机接受帕唑帕尼800mg每日一次或安慰剂52周。研究未达到主要终点,帕唑帕尼组3年无病生存率27.4%对比安慰剂组21.9%(HR 0.90,P单侧=0.29),总生存反而倾向安慰剂组(HR 2.55,P双侧=0.012)。
要点
- 帕唑帕尼未改善转移灶切除术后无疾病证据患者的无病生存,研究未达主要终点。
- 3年无病生存率帕唑帕尼组27.4%对比安慰剂组21.9%,HR 0.90,未达统计学显著。
- 总生存倾向安慰剂组,HR 2.55(95%CI 1.23-5.27),P双侧=0.012。
核心结论
- 帕唑帕尼对比盲法安慰剂未改善转移灶切除术后无疾病证据的转移性肾细胞癌患者的无病生存这一主要终点。
- 此外,总生存存在倾向安慰剂组的令人担忧趋势。
研究设计与样本
- 随机、双盲、安慰剂对照的多中心III期研究。
- 纳入转移灶切除术后无疾病证据的转移性肾细胞癌患者,1:1随机分配接受帕唑帕尼800mg每日一次或安慰剂,疗程52周。
- 研究设计预期帕唑帕尼组3年无病生存率从25%提高至45%,对应无病生存事件率降低42%。
- 2012年8月至2017年7月共入组129例患者。
- 发生83例无病生存事件(92%信息量)后揭盲。
主要发现
- 从随机分组起中位随访60.5个月(95%CI 59.3-71.0)的更新分析显示,3年无病生存率帕唑帕尼组为27.4%(95%CI 17.9-41.7),安慰剂组为21.9%(95%CI 13.3-36.2)。
- 无病生存的风险比(HR)为0.90(95%CI 0.60-1.34;P单侧=0.29),倾向帕唑帕尼。
- 3年总生存率帕唑帕尼组为81.9%(95%CI 72.7-92.2),安慰剂组为91.4%(95%CI 84.4-98.9)。
- 总生存的HR为2.55(95%CI 1.23-5.27),倾向安慰剂(P双侧=0.012)。
- 治疗期间帕唑帕尼组的健康相关生活质量指标出现恶化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with no evidence of disease (NED) after metastasectomy for renal cell carcinoma are at high risk of recurrence. Pazopanib is an inhibitor of vascular endothelial growth factor receptor and other kinases that improves progression-free survival in patients with metastatic RCC (mRCC). We conducted a randomized, double-blind, placebo-controlled multicenter study to test whether pazopanib would improve disease-free survival (DFS) in patients with mRCC rendered NED after metastasectomy. PATIENTS AND METHODS: Patients with NED after metastasectomy were randomly assigned 1:1 to receive pazopanib 800 mg once daily versus placebo for 52 weeks. The study was designed to observe an improvement in DFS from 25% to 45% with pazopanib at 3 years, corresponding to 42% reduction in the DFS event rate. RESULTS: From August 2012 to July 2017, 129 patients were enrolled. The study was unblinded after 83 DFS events (92% information). The study did not meet its primary end point. An updated analysis at 60.5-month median follow-up from random assignment (95% CI, 59.3 to 71.0) showed that the 3-year DFS was 27.4% (95% CI, 17.9 to 41.7) for pazopanib and 21.9% (95% CI, 13.3 to 36.2) for placebo. Hazard ratio (HR) for DFS was 0.90 ([95% CI, 0.60 to 1.34]; Pone-sided = .29) in favor of pazopanib. Three-year overall survival (OS) was 81.9% (95% CI, 72.7 to 92.2) for pazopanib and 91.4% (95% CI, 84.4 to 98.9) for placebo. The HR for OS was 2.55 (95% CI, 1.23 to 5.27) in favor of placebo (Ptwo-sided = .012). Health-related quality-of-life measures deteriorated in the pazopanib group during the treatment period. CONCLUSION: Pazopanib did not improve DFS as the primary end point compared with blinded placebo in patients with mRCC with NED after metastasectomy. In addition, there was a concerning trend favoring placebo in OS.
引用
- Appleman LJ, Kim SE, Harris WB, et al. Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810. J Clin Oncol. 2024. PMID: 38531002. doi:10.1200/JCO.23.01544
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。